Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fragrance Mix + Thimerosal is a combination of standardized allergens used as a diagnostic tool within the T.R.U.E. TEST (Thin-layer Rapid Use Epicutaneous Test) system. Developed by Allerderm, this product is specifically designed to identify allergic contact dermatitis (ACD) in patients with suspected sensitivities to common fragrance ingredients or the preservative thimerosal. The fragrance mix component consists of eight distinct substances: geraniol, cinnamaldehyde, hydroxycitronellal, cinnamyl alcohol, eugenol, isoeugenol, alpha-amylcinnamaldehyde, and oak moss. Thimerosal is a mercury-based preservative often found in cosmetics and vaccines. The allergens are formulated in a hydrophilic polymer gel (such as povidone) on a polyester patch. When applied to the skin, perspiration hydrates the gel, releasing the allergens to penetrate the epidermis and trigger a delayed-type (Type IV) hypersensitivity reaction in sensitized individuals, mediated by T-lymphocytes and Langerhans cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fragrance mix + thimerosal.